1. Signaling Pathways
  2. Neuronal Signaling
  3. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W011727
    Pyridoxal 5'-phosphate hydrate
    Inhibitor 99.76%
    Pyridoxal 5'-phosphate hydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate hydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′-phosphate (PMP).
    Pyridoxal 5'-phosphate hydrate
  • HY-139324
    Cu(II)GTSM
    Inhibitor
    Cu(II)GTSM, a cell-permeable Cu-complex, significantly inhibits GSK3β. Cu(II)GTSM inhibits Amyloid-β oligomers (AβOs) and decreases tau phosphorylation. Cu(II)GTSM also decreases the abundance of Amyloid-β trimers. Cu(II)GTSM is a potential anticancer and antimicrobial agent.
    Cu(II)GTSM
  • HY-N1487
    Oleanonic acid
    Inhibitor 99.63%
    Oleanonic acid (3-Oxooleanolic acid) is an orally available triterpene that has anti-inflammatory and insecticidal properties. In vitro, oleanonic acid can improve oxidative stress, autophagy defects, ferroptosis, mitochondrial damage, and endoplasmic reticulum stress induced by Amyloid-β, and in vivo, it can alleviate myocardial hypertrophy in rats.
    Oleanonic acid
  • HY-N0148R
    Rutin (Standard)
    Inhibitor
    Rutin (Standard) is the analytical standard of Rutin. This product is intended for research and analytical applications. Rutin (Rutoside) is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin is also a CBR1 inhibitor, which can cross the blood brain barrier. Rutin attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress.
    Rutin (Standard)
  • HY-P2550A
    β-Amyloid (1-40), FAM-labeled TFA
    99.71%
    β-Amyloid (1-40), FAM-labeled TFA is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λex= 492 nm and λem= 518 nm).
    β-Amyloid (1-40), FAM-labeled TFA
  • HY-N1570
    Pterosin B
    Inhibitor 99.98%
    Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes.
    Pterosin B
  • HY-P991045
    Donanemab (Mouse IgG2a)
    99%
    Donanemab (Mouse IgG2a) (mE8-IgG2a) is a mouse-derived IgG2 monoclonal antibody used in the research of Alzheimer's disease.
    Donanemab (Mouse IgG2a)
  • HY-P4808A
    PHF6 TFA
    99.03%
    PHF6 (VQIVYK) TFA is a self-assembly sequence capable of initiating the full-length tau protein aggregation. PHF6 TFA is mapped to the third microtubule-binding repeat region of the tau protein.
    PHF6 TFA
  • HY-125962
    X-34
    X-34 is a lipophilic and bright yellow-green fluorescent derivative of Congo red (HY-D0236). X-34 can be used to stain neuritic and diffuse plaques, neurofibrillary tangles (NFTs), neuropil threads, and cerebrovascular amyloid in the brain. X-34 can be used for research of Alzheimer’s disease.
    X-34
  • HY-P5124
    β-Amyloid peptide(16-20)
    Inhibitor 99.95%
    β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of Amyloid-β (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH2 residues added at N- and C-terminal ends to aid solubility).
    β-Amyloid peptide(16-20)
  • HY-136500
    Prostaglandin H2
    Activator
    Prostaglandin H2 (PGH2) is an endothelium-derived contracting factor. Prostaglandin H2 can cause vasoconstriction. Prostaglandin H2 is the common precursor of all PGs and is produced by several cells that express cyclooxygen-ases. Prostaglandin H2 can activate PGD2 receptors CRTH2 and DP via interacting directly with the receptors and/or by giving rise to PGD2 after catalytic conversion by plasma proteins. Prostaglandin H2 can induce eosinophils migration and inhibit platelet aggregation. Prostaglandin H2 can accelerate the formation of dimers and higher oligomers of amyloid β1-42. Prostaglandin H2 can be used for the researches of inflammation and neurological disease, such as Alzheimer disease.
    Prostaglandin H2
  • HY-117259
    Valiltramiprosate
    Inhibitor 98.83%
    ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease.
    Valiltramiprosate
  • HY-124322
    NB-360
    Inhibitor 99.08%
    NB-360 is a potent, brain penetrable and orally active β‐secretase 1/2 (BACE1/BACE2) dual inhibitor with IC50 values of 5 and 6 nM. NB-360 can inhibit amyloid-β protein accumulation. NB-360 can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease.
    NB-360
  • HY-P990078
    Remternetug
    Inhibitor 99.00%
    Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of . Remternetug results in rapid and robust amyloid plaque reduction. Remternetug can be used for Alzheimer's disease research.
    Remternetug
  • HY-N0651
    Spinosin
    Inhibitor 99.39%
    Spinosyn is a kind of effective C-saccharide, which has a protective effect. Spinosyn is active through Nrf2/HO-1 pathway inhibition Aβ1-42's production and combination[3 ].
    Spinosin
  • HY-B1786A
    (E/Z)-Sulindac sulfide
    Inhibitor 99.88%
    (E/Z)-Sulindac sulfide is a potent γ-secretase modulator (GSM). (E/Z)-Sulindac sulfide selectively reduces Aβ42 production in favor of shorter species. (E/Z)-Sulindac sulfide can be used for researching Alzheimer’s disease.
    (E/Z)-Sulindac sulfide
  • HY-136780
    SEN177
    Inhibitor 98.76%
    SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The Ki of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC50 is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases.
    SEN177
  • HY-W748591
    Cannflavin A
    Inhibitor 99.20%
    Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits 1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC50 = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line.
    Cannflavin A
  • HY-103242
    CRANAD-2
    ≥98.0%
    CRANAD-2 is a near-infrared (NIR) Aβ plaque-specific fluorescent probe. CRANAD 2 penetrates the blood brain barrier and has a high affinity for Aβ aggregates with a Kd of 38 nM.
    CRANAD-2
  • HY-P99835
    Crenezumab
    Inhibitor 99.86%
    Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research.
    Crenezumab
Cat. No. Product Name / Synonyms Application Reactivity